The relationship between metabolic syndrome and the incidence of colorectal cancer

Lee, Jung-Hyun; Lee, Kun Sei; Kim, Hyeong-Su; Jeong, Hyoseon; Choi, Min‐Jung; Yoo, Hai-Won; Han, Taehwa; Lee, Hyunjung

doi:10.1186/s12199-020-00845-w

Cited by 41 publications

(34 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 2001, several epidemiological studies have investigated the association between MetS and CRC risk but showed inconsistent results. As some studies showed that, MetS plays an important role in CRC [15][16][17]. However, there were also studies showed no significant correlation between the two [18][19][20][21][22].…”

Section: Ivyspringmentioning

confidence: 95%

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

Han¹,

Wu²,

Zhang³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Background: This meta-analysis was aimed to quantitatively assess the associations of metabolic syndrome (MetS) and its components with colorectal cancer (CRC). Methods: PubMed, EMBASE and Web of Science databases were systematically searched for eligible studies. A total of 18 studies for CRC incidence and 12 studies for CRC mortality were identified. Results: MetS was associated with an increased risk of CRC incidence and mortality in male (RR: 1.28, 95 % CI 1.16-1.39, and 1.24, 1.18-1.31, respectively) and correlated with an increased risk of CRC incidence in female (RR: 1.21, 1.13-1.30), but not with CRC mortality in female. MetS increased the risk of cancer-specific mortality (RR: 1.72, 1.03-2.42), but not overall mortality. The risk estimates of CRC incidence changed little depending on age, sex, cancer site, the type of studies, ethnicity, publication year, or definition of MetS. As for CRC mortality, further stratified analyses indicated statistical significance in studies with assessing cancer-specific survival outcome, in male, a cohort design, ethnicity of non-Chinese or with definition of MetS as ≥ 3 metabolic abnormalities. Obesity and hyperglycemia are risk factors of CRC incidence in both male and female. Only dysglycemia is the risk factor for CRC mortality. Conclusions: MetS is associated with an increased risk of CRC incidence and cancer-specific mortality, but not overall mortality. In addition, MetS may increase the CRC mortality in male rather than in female. However, since most of the studies on CRC mortality were conducted in Chinese, further studies are needed to clarify this connection.

show abstract

Section: Ivyspringmentioning

confidence: 95%

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

Han¹,

Wu²,

Zhang³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…Furthermore, the metabolic syndrome [31], a well-known obesity associated condition [32], increases the risk of developing [33] and having relapse in colorectal cancer [34,35].…”

Section: Obesity and Cancer: Prognosis And Mortalitymentioning

confidence: 99%

Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis

2021

View full text Add to dashboard Cite

The prevalence of being overweight and obese has been expanded dramatically in recent years worldwide. Obesity usually occurs when the energetic introit overtakes energy expenditure from metabolic and physical activity, leading to fat accumulation mainly in the visceral depots. Excessive fat accumulation represents a risk factor for many chronic diseases, including cancer. Adiposity, chronic low-grade inflammation, and hyperinsulinemia are essential factors of obesity that also play a crucial role in tumor onset. In recent years, several strategies have been pointed toward boundary fat accumulation, thus limiting the burden of cancer attributable to obesity. While remodeling fat via adipocytes browning seems a tempting prospect, lifestyle interventions still represent the main pathway to prevent cancer and enhance the efficacy of treatments. Specifically, the Mediterranean Diet stands out as one of the best dietary approaches to curtail visceral adiposity and, therefore, cancer risk. In this Review, the close relationship between obesity and cancer has been investigated, highlighting the biological mechanisms at the basis of this link. Finally, strategies to remodel fat, including browning and lifestyle interventions, have been taken into consideration as a major perspective to limit excess body weight and tumor onset.

show abstract

“…Colorectal cancer (CRC) is also attributed to overweight and obesity [ 108 ] and available data suggest that CRC risk is positively correlated with many factors, including metabolic syndrome [ 109 ] or leptin levels [ 110 ]. Some studies reported no associations between high serum leptin levels and CRC [ 111 , 112 ], but the majority described the overexpression of both leptin and Ob-R correlated with tumor progression [ 113 , 114 , 115 , 116 , 117 ].…”

Section: Role Of Leptin As a Bad Actor In Cancermentioning

confidence: 99%

Leptin, Both Bad and Good Actor in Cancer

Jiménez‐Cortegana¹,

López-Saavedra²,

Sánchez-Jiménez³

et al. 2021

Biomolecules

View full text Add to dashboard Cite

Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the “obesity paradox”, and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology.

show abstract

The relationship between metabolic syndrome and the incidence of colorectal cancer

Cited by 41 publications

References 42 publications

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis

Leptin, Both Bad and Good Actor in Cancer

Contact Info

Product

Resources

About